Simplify Logo

Full-Time

Clinical Scientist

Cell Therapy

Posted on 7/23/2024

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Data & Analytics
Consulting
Consumer Software
Fintech
Social Impact
Biotechnology
Healthcare

Compensation Overview

$156k - $208kAnnually

+ Incentive Cash + Stock Opportunities

Entry

Seattle, WA, USA + 2 more

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Management
Word/Pages/Docs
PowerPoint/Keynote/Slides
Requirements
  • Degree in Life Sciences (MD, PhD, Pharm D, MS, RN or other scientific field preferred)
  • Basic knowledge of GCP/ICH, drug development process, study design, statistics, clinical operations
  • Intermediate medical writing skills and medical terminology
  • Basic planning/project management skills
  • Detail-oriented with commitment to quality
  • Basic knowledge of disease area, compound, current clinical landscape
  • Intermediate critical thinking and problem-solving skills
  • Adaptable / flexible
  • Intermediate skills in Microsoft Word/Excel/PowerPoint and data review tools
Responsibilities
  • Collaborate and liaise with external partners (e.g., KOLs)
  • Seek out and enact best practices with instruction
  • Provide regular and timely updates to manager/management as requested
  • Develop Protocol and ICF documents / amendments and present these to governance committee and development team meetings as required
  • Conduct literature review
  • Submit clinical documents to TMF
  • Develop site and CRA training materials and present these at SIVs and Investigator meetings
  • Review clinical narratives
  • Monitor clinical data for specific trends
  • Develop Data Review Plan in collaboration with Data Management
  • Ensure CRF design adequately supports data collection in alignment with the protocol
  • Submit clinical contributions to clinical study reports (CSRs) and clinical portions of Regulatory Documents
  • Domestic and International travel may be required

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are then sold after receiving regulatory approval. BMS also produces generic drugs, providing affordable alternatives that maintain the same quality and safety standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while adhering to sustainability and corporate responsibility principles.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's involvement in Nobel Prize-winning immunology research underscores its leadership in groundbreaking scientific advancements.
  • The robust pipeline of molecular glues and other innovative therapies promises significant revenue growth and market expansion.
  • Recognition in the Dow Jones Sustainability Index North America highlights BMS's commitment to corporate responsibility and sustainability, enhancing its reputation and stakeholder trust.

What critics are saying

  • The termination of strategic collaborations, such as with Eisai, could impact BMS's ability to bring new therapies to market efficiently.
  • Ongoing layoffs and restructuring efforts may lead to decreased employee morale and potential disruptions in operations.

What makes Bristol-Myers Squibb unique

  • Bristol Myers Squibb's dual focus on innovative and generic medicines allows it to cater to a broad spectrum of healthcare needs, unlike competitors who may focus solely on one area.
  • Their commitment to sustainability and ESG goals sets them apart in the biopharmaceutical industry, appealing to socially conscious investors and stakeholders.
  • BMS's extensive R&D investment in oncology, immunology, and cardiovascular diseases positions it as a leader in developing cutting-edge treatments for serious diseases.
INACTIVE